<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38789394</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1747-0285</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Chemical biology &amp; drug design</Title><ISOAbbreviation>Chem Biol Drug Des</ISOAbbreviation></Journal><ArticleTitle>Phenotypic assessment of antiviral activity for spiro-annulated oxepanes and azepenes.</ArticleTitle><Pagination><StartPage>e14553</StartPage><MedlinePgn>e14553</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cbdd.14553</ELocationID><Abstract><AbstractText>Evolutionary potential of viruses can result in outbreaks of well-known viruses and emergence of novel ones. Pharmacological methods of intervening the reproduction of various less popular, but not less important viruses are not available, as well as the spectrum of antiviral activity for most known compounds. In the framework of chemical biology paradigm, characterization of antiviral activity spectrum of new compounds allows to extend the antiviral chemical space and provides new important structure-activity relationships for data-driven drug discovery. Here we present a primary assessment of antiviral activity of spiro-annulated derivatives of seven-membered heterocycles, oxepane and azepane, in phenotypic assays against viruses with different genomes, virion structures, and genome realization schemes: orthoflavivirus (tick-borne encephalitis virus, TBEV), enteroviruses (poliovirus, enterovirus A71, echovirus 30), adenovirus (human adenovirus C5), hantavirus (Puumala virus). Hit compounds inhibited reproduction of adenovirus C5, the only DNA virus in the studied set, in the yield reduction assay, and did not inhibit reproduction of RNA viruses.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osolodkin</LastName><ForeName>Dmitry I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozlovskaya</LastName><ForeName>Liubov I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iusupov</LastName><ForeName>Ildar R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurkin</LastName><ForeName>Alexander V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shustova</LastName><ForeName>Elena Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orlov</LastName><ForeName>Alexey A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khvatov</LastName><ForeName>Evgeny V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutnykh</LastName><ForeName>Elena S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurashova</LastName><ForeName>Svetlana S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vetrova</LastName><ForeName>Anna N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatsenko</LastName><ForeName>Darya O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goryashchenko</LastName><ForeName>Alexander S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanov</LastName><ForeName>Vladimir N</ForeName><Initials>VN</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukyanenko</LastName><ForeName>Evgeny R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karpova</LastName><ForeName>Evgenia V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stepanova</LastName><ForeName>Daria A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volok</LastName><ForeName>Viktor P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotskova</LastName><ForeName>Svetlana E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dzagurova</LastName><ForeName>Tamara K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karganova</LastName><ForeName>Galina G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukashev</LastName><ForeName>Alexander N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishmukhametov</LastName><ForeName>Aydar A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Russian Science Foundation</Agency><Country /></Grant><Grant><Agency>Russian Foundation for Basic Research</Agency><Country /></Grant><Grant><Agency>Ministry of Science and Higher Education of the Russian Federation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chem Biol Drug Des</MedlineTA><NlmUniqueID>101262549</NlmUniqueID><ISSNLinking>1747-0277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010082">Oxepins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013141" MajorTopicYN="N">Spiro Compounds</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010082" MajorTopicYN="N">Oxepins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2,3,4,7‐tetrahydrooxepine</Keyword><Keyword MajorTopicYN="N">2,3,4,7‐tetrahydro‐1H‐azepine</Keyword><Keyword MajorTopicYN="N">adenovirus</Keyword><Keyword MajorTopicYN="N">antiviral activity</Keyword><Keyword MajorTopicYN="N">azepane</Keyword><Keyword MajorTopicYN="N">oxepane</Keyword><Keyword MajorTopicYN="N">phenotypic screening</Keyword><Keyword MajorTopicYN="N">spirocycle</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>24</Day><Hour>22</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38789394</ArticleId><ArticleId IdType="doi">10.1111/cbdd.14553</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Baltimore, D. (1971). Expression of animal virus genomes. Bacteriological Reviews, 35, 235–241. https://doi.org/10.1128/br.35.3.235‐241.1971</Citation></Reference><Reference><Citation>Barbero, H., Díez‐Poza, C., &amp; Barbero, A. (2017). The oxepane motif in marine drugs. Marine Drugs, 15(11), 361. https://doi.org/10.3390/md15110361</Citation></Reference><Reference><Citation>Barklis, E., Still, A., Sabri, M. I., Hirsch, A. J., Nikolich‐Zugich, J., Brien, J., Dhenub, T. C., Scholz, I., &amp; Alfadhli, A. (2007). Sultam thiourea inhibition of West Nile virus. Antimicrobial Agents and Chemotherapy, 51, 2642–2645. https://doi.org/10.1128/AAC.00007‐07</Citation></Reference><Reference><Citation>Basu, S., Ellinger, B., Rizzo, S., Deraeve, C., Schürmann, M., Preut, H., Arndt, H.‐D., &amp; Waldmann, H. (2011). Biology‐oriented synthesis of a natural‐product inspired oxepane collection yields a small‐molecule activator of the Wnt‐pathway. Proceedings of the National Academy of Sciences of the United States of America, 108(17), 6805–6810. https://doi.org/10.1073/pnas.1015269108</Citation></Reference><Reference><Citation>Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., Nowotka, M., Papadatos, G., Santos, R., &amp; Overington, J. P. (2014). The ChEMBL bioactivity database: An update. Nucleic Acids Research, 42, D1083–D1090. https://doi.org/10.1093/nar/gkt1031</Citation></Reference><Reference><Citation>Burgeson, J. R., Moore, A. L., Boutilier, J. K., Cerruti, N. R., Gharaibeh, D. N., Lovejoy, C. E., Amberg, S. M., Hruby, D. E., Tyavanagimatt, S. R., Allen, R. D., &amp; Dai, D. (2012). SAR analysis of a series of acylthiourea derivatives possessing broad‐spectrum antiviral activity. Bioorganic &amp; Medicinal Chemistry Letters, 22, 4263–4272. https://doi.org/10.1016/j.bmcl.2012.05.035</Citation></Reference><Reference><Citation>Cenciarelli, O., Pietropaoli, S., Malizia, A., Carestia, M., D'Amico, F., Sassolini, A., Di Giovanni, D., Rea, S., Gabbarini, V., Tamburrini, A., Palombi, L., Bellecci, C., &amp; Gaudio, P. (2015). Ebola virus disease 2013–2014 outbreak in West Africa: An analysis of the epidemic spread and response. International Journal of Microbiology, 2015, 1–12. https://doi.org/10.1155/2015/769121</Citation></Reference><Reference><Citation>Chistov, A. A., Orlov, A. A., Streshnev, P. P., Slesarchuk, N. A., Aparin, I. O., Rathi, B., Brylev, V. A., Kutyakov, S. V., Mikhura, I. V., Ustinov, A. V., Westman, G., Palyulin, V. A., Jain, N., Osolodkin, D. I., Kozlovskaya, L. I., &amp; Korshun, V. A. (2019). Compounds based on 5‐(perylen‐3‐ylethynyl)uracil scaffold: High activity against tick‐borne encephalitis virus and non‐specific activity against enterovirus A. European Journal of Medicinal Chemistry, 171, 93–103. https://doi.org/10.1016/j.ejmech.2019.03.029</Citation></Reference><Reference><Citation>Chung, D.‐H., Kumarapperuma, S. C., Sun, Y., Li, Q., Chu, Y.‐K., Arterburn, J. B., Parker, W. B., Smith, J., Spik, K., Ramanathan, H. N., Schmaljohn, C. S., &amp; Jonsson, C. B. (2008). Synthesis of 1‐β‐d‐ribofuranosyl‐3‐ethynyl‐[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antiviral Research, 79, 19–27. https://doi.org/10.1016/j.antiviral.2008.02.003</Citation></Reference><Reference><Citation>De Clercq, E. (2012). Human viral diseases: What is next for antiviral drug discovery? Current Opinion in Virology, 2, 572–579. https://doi.org/10.1016/j.coviro.2012.07.004</Citation></Reference><Reference><Citation>De Clercq, E., &amp; Li, G. (2016). Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews, 29, 695–747. https://doi.org/10.1128/CMR.00102‐15</Citation></Reference><Reference><Citation>De Lourdes, G., Ferreira, M., Pinheiro, L. C. S., Santos‐Filho, O. A., Peçanha, M. D. S., Sacramento, C. Q., Machado, V., Ferreira, V. F., Souza, T. M. L., &amp; Boechat, N. (2014). Design, synthesis, and antiviral activity of new 1H‐1,2,3‐triazole nucleoside ribavirin analogs. Medicinal Chemistry Research, 23, 1501–1511. https://doi.org/10.1007/s00044‐013‐0762‐6</Citation></Reference><Reference><Citation>Deng, H., Luo, F., Shi, L., Zhong, Q., Liu, Y., &amp; Yang, Z. (2009). Efficacy of arbidol on lethal hantaan virus infections in suckling mice and in vitro. Acta Pharmacologica Sinica, 30, 1015–1024. https://doi.org/10.1038/aps.2009.53</Citation></Reference><Reference><Citation>Dzagurova, T., Tkachenko, E., Slonova, R., Ivanov, L., Ivanidze, E., Markeshin, S., Dekonenko, A., Niklasson, B., &amp; Lundkvist, Å. (1995). Antigenic relationships of hantavirus strains analysed by monoclonal antibodies. Archives of Virology, 140, 1763–1773. https://doi.org/10.1007/BF01384340</Citation></Reference><Reference><Citation>Dzagurova, T. K., Klempa, B., Tkachenko, E. A., Slyusareva, G. P., Morozov, V. G., Auste, B., &amp; Kruger, D. H. (2009). Molecular diagnostics of hemorrhagic fever with renal syndrome during a Dobrava virus infection outbreak in the European part of Russia. Journal of Clinical Microbiology, 47, 4029–4036. https://doi.org/10.1128/jcm.01225‐09</Citation></Reference><Reference><Citation>Faria, N. R., Azevedo, R. D. S. D. S., Kraemer, M. U. G., Souza, R., Cunha, M. S., Hill, S. C., Thézé, J., Bonsall, M. B., Bowden, T. A., Rissanen, I., Rocco, I. M., Nogueira, J. S., Maeda, A. Y., Vasami, F. G. S., Macedo, F. L. L., Suzuki, A., Rodrigues, S. G., Cruz, A. C. R., Nunes, B. T., … Vasconcelos, P. F. C. (2016). Zika virus in the Americas: Early epidemiological and genetic findings. Science, 352, 345–349. https://doi.org/10.1126/science.aaf5036</Citation></Reference><Reference><Citation>Goryashchenko, A. S., Uvarova, V. I., Osolodkin, D. I., &amp; Ishmukhametov, A. A. (2022). Discovery of small molecule antivirals targeting tick‐borne encephalitis virus. In D. I. Osolodkin (Ed.), Annual reports in medicinal chemistry (Vol. 58, pp. 1–54). Academic Press.</Citation></Reference><Reference><Citation>Iusupov, I. R., &amp; Kurkin, A. V. (2024). Stereoselective synthesis of spirocyclic derivatives of functionalized 2,3,4,7‐tetrahydro‐1H‐azepines. Mendeleev Communications, 34, 209–211. https://doi.org/10.1016/j.mencom.2024.02.016</Citation></Reference><Reference><Citation>Iusupov, I. R., Lukyanenko, E. R., Altieri, A., &amp; Kurkin, A. V. (2022). Design and synthesis of Fsp3‐enriched spirocyclic‐based biological screening compound arrays via DOS strategies and their NNMT inhibition profiling. ChemMedChem, 17, e202200394. https://doi.org/10.1002/cmdc.202200394</Citation></Reference><Reference><Citation>Iusupov, I. R., Lyssenko, K. A., Altieri, A., &amp; Kurkin, A. V. (2022). (1RS,2RS,6RS)‐2‐(6‐Amino‐9H‐purin‐9‐yl)‐8‐azaspiro[5.6]dodec‐10‐en‐1‐ol dihydrochloride. Molbank, 2022, M1495. https://doi.org/10.3390/M1495</Citation></Reference><Reference><Citation>Ivanova, O. E., Yurashko, O. V., Eremeeva, T. P., Baikova, O. Y., Morozova, N. S., &amp; Lukashev, A. N. (2012). Adenovirus isolation rates in acute flaccid paralysis patients. Journal of Medical Virology, 84, 75–80. https://doi.org/10.1002/jmv.22265</Citation></Reference><Reference><Citation>Jiang, X., Su, H., Shang, W., Zhou, F., Zhang, Y., Zhao, W., Zhang, Q., Xie, H., Jiang, L., Nie, T., Yang, F., Xiong, M., Huang, X., Li, M., Chen, P., Peng, S., Xiao, G., Jiang, H., Tang, R., … Xu, Y. (2023). Structure‐based development and preclinical evaluation of the SARS‐CoV‐2 3C‐like protease inhibitor simnotrelvir. Nature Communications, 14, 6463. https://doi.org/10.1038/s41467‐023‐42102‐y</Citation></Reference><Reference><Citation>Kärber, G. (1931). Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn‐Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie, 162, 480–483. https://doi.org/10.1007/BF01863914</Citation></Reference><Reference><Citation>Kojaoghlanian, T., Flomenberg, P., &amp; Horwitz, M. S. (2003). The impact of adenovirus infection on the immunocompromised host. Reviews in Medical Virology, 13, 155–171. https://doi.org/10.1002/rmv.386</Citation></Reference><Reference><Citation>Kozlovskaya, L. I., Golinets, A. D., Eletskaya, A. A., Orlov, A. A., Palyulin, V. A., Kochetkov, S. N., Alexandrova, L. A., &amp; Osolodkin, D. I. (2018). Selective inhibition of Enterovirus A species members' reproduction by furano[2,3‐d]pyrimidine nucleosides revealed by antiviral activity profiling against (+)ssRNA viruses. ChemistrySelect, 3, 2321–2325. https://doi.org/10.1002/slct.201703052</Citation></Reference><Reference><Citation>Lovering, F. (2013). Escape from flatland 2: Complexity and promiscuity. Medicinal Chemistry Communications, 4(3), 515. https://doi.org/10.1039/c2md20347b</Citation></Reference><Reference><Citation>Lovering, F., Bikker, J., &amp; Humblet, C. (2009). Escape from flatland: Increasing saturation as an approach to improving clinical success. Journal of Medicinal Chemistry, 52(21), 6752–6756. https://doi.org/10.1021/jm901241e</Citation></Reference><Reference><Citation>Lugthart, G., Oomen, M. A., Jol‐van Der Zijde, C. M., Ball, L. M., Bresters, D., Kollen, W. J. W., Smiers, F. J., Vermont, C. L., Bredius, R. G. M., Schilham, M. W., van Tol, M. J., &amp; Lankester, A. C. (2015). The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution. Biology of Blood and Marrow Transplantation, 21, 293–299. https://doi.org/10.1016/j.bbmt.2014.10.012</Citation></Reference><Reference><Citation>Martínez‐Aguado, P., Serna‐Gallego, A., Marrugal‐Lorenzo, J. A., Gómez‐Marín, I., &amp; Sánchez‐Céspedes, J. (2015). Antiadenovirus drug discovery: Potential targets and evaluation methodologies. Drug Discovery Today, 20, 1235–1242. https://doi.org/10.1016/j.drudis.2015.07.007</Citation></Reference><Reference><Citation>Matthes‐Martin, S., Boztug, H., &amp; Lion, T. (2013). Diagnosis and treatment of adenovirus infection in immunocompromised patients. Expert Review of Anti‐Infective Therapy, 11, 1017–1028. https://doi.org/10.1586/14787210.2013.836964</Citation></Reference><Reference><Citation>Meyer‐Rüsenberg, B., Loderstädt, U., Richard, G., Kaulfers, P.‐M., &amp; Gesser, C. (2011). Epidemic keratoconjunctivitis: The current situation and recommendations for prevention and treatment. Deutsches Ärzteblatt International, 108, 475–480. https://doi.org/10.3238/arztebl.2011.0475</Citation></Reference><Reference><Citation>Mykura, R., Sánchez‐Bento, R., Matador, E., Duong, V. K., Varela, A., Angelini, L., Carbajo, R. J., Llaveria, J., Ruffoni, A., &amp; Leonori, D. (2024). Synthesis of polysubstituted azepanes by dearomative ring expansion of nitroarenes. Nature Chemistry, 16, 771–779. https://doi.org/10.1038/s41557‐023‐01429‐1</Citation></Reference><Reference><Citation>Nikitina, A. A., Orlov, A. A., Kozlovskaya, L. I., Palyulin, V. A., &amp; Osolodkin, D. I. (2019). Enhanced taxonomy annotation of antiviral activity data from ChEMBL. Database, 2019, bay139. https://doi.org/10.1093/database/bay139</Citation></Reference><Reference><Citation>Nortcliffe, A., &amp; Moody, C. J. (2015). Seven‐membered ring scaffolds for drug discovery: Access to functionalised azepanes and oxepanes through diazocarbonyl chemistry. Bioorganic &amp; Medicinal Chemistry, 23(11), 2730–2735. https://doi.org/10.1016/j.bmc.2015.01.010</Citation></Reference><Reference><Citation>Orlov, A. A., Chistov, A. A., Kozlovskaya, L. I., Ustinov, A. V., Korshun, V. A., Karganova, G. G., &amp; Osolodkin, D. I. (2016). Rigid amphipathic nucleosides suppress reproduction of the tick‐borne encephalitis virus. Medicinal Chemistry Communications, 7, 495–499. https://doi.org/10.1039/C5MD00538H</Citation></Reference><Reference><Citation>Pinto, A., Beck, R., &amp; Jadavji, T. (1992). Fatal neonatal pneumonia caused by adenovirus type 35. Report of one case and review of the literature. Archives of Pathology &amp; Laboratory Medicine, 116, 95–99.</Citation></Reference><Reference><Citation>Proenca‐Modena, J. L., Pereira Valera, F. C., Jacob, M. G., Buzatto, G. P., Saturno, T. H., Lopes, L., Souza, J. M., Paula, F. E., Silva, M. L., Carenzi, L. R., Tamashiro, E., Arruda, E., &amp; Anselmo‐Lima, W. T. (2012). High rates of detection of respiratory viruses in tonsillar tissues from children with chronic adenotonsillar disease. PLoS One, 7, e42136. https://doi.org/10.1371/journal.pone.0042136</Citation></Reference><Reference><Citation>Reed, L. J., &amp; Muench, H. (1938). A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology, 27, 493–497. https://doi.org/10.1093/oxfordjournals.aje.a118408</Citation></Reference><Reference><Citation>Sanchez‐Cespedes, J., Moyer, C. L., Whitby, L. R., Boger, D. L., &amp; Nemerow, G. R. (2014). Inhibition of adenovirus replication by a trisubstituted piperazin‐2‐one derivative. Antiviral Research, 108, 65–73. https://doi.org/10.1016/j.antiviral.2014.05.010</Citation></Reference><Reference><Citation>Sedenkova, K. N., Dueva, E. V., Averina, E. B., Grishin, Y. K., Osolodkin, D. I., Kozlovskaya, L. I., Palyulin, V. A., Savelyev, E. N., Orlinson, B. S., Novakov, I. A., Butov, G. M., Kuznetsova, T. S., Karganova, G. G., &amp; Zefirov, N. S. (2015). Synthesis and assessment of 4‐aminotetrahydroquinazoline derivatives as tick‐borne encephalitis virus reproduction inhibitors. Organic &amp; Biomolecular Chemistry, 13, 3406–3415. https://doi.org/10.1039/C4OB02649G</Citation></Reference><Reference><Citation>Sedenkova, K. N., Sazonov, A. S., Vasilenko, D. A., Andriasov, K. S., Eremenko, M. G., Grishin, Y. K., Khvatov, E. V., Goryashchenko, A. S., Uvarova, V. I., Osolodkin, D. I., Ishmukhametov, A. A., &amp; Averina, E. B. (2023). 3‐[N,N‐Bis(sulfonyl)amino]isoxazolines with spiro‐annulated or 1,2‐annulated cyclooctane rings inhibit reproduction of tick‐borne encephalitis, yellow fever, and West Nile viruses. International Journal of Molecular Sciences, 24(13), 10758. https://doi.org/10.3390/ijms241310758</Citation></Reference><Reference><Citation>Sedenkova, K. N., Uvarova, V. I., Nazarova, A. A., Peisikova, A. V., Khvatov, E. V., Sukhorukov, M. V., Frolenko, V. S., Goryashchenko, A. S., Kholodilov, I. S., Grishin, Y. K., Rybakov, V. B., Makenov, M. T., Morozkin, E. S., Karan, L. S., Kozlovskaya, L. I., Ishmukhametov, A. A., Osolodkin, D. I., &amp; Averina, E. B. (2023). Tetrahydroquinazoline N‐oxide derivatives inhibit reproduction of tick‐borne and mosquito‐borne flaviviruses. Archiv der Pharmazie, 356, 2300027. https://doi.org/10.1002/ardp.202300027</Citation></Reference><Reference><Citation>Sirivolu, V. R., Vernekar, S. K. V., Ilina, T., Myshakina, N. S., Parniak, M. A., &amp; Wang, Z. (2013). Clicking 3′‐azidothymidine into novel potent inhibitors of human immunodeficiency virus. Journal of Medicinal Chemistry, 56, 8765–8780. https://doi.org/10.1021/jm401232v</Citation></Reference><Reference><Citation>Sperandio, D., &amp; Mackman, R. (2013). Respiratory syncytial virus fusion inhibitors. In M. C. Desai &amp; N. A. Meanwell (Eds.), Successful strategies for the discovery of antiviral drugs (pp. 29–62). The Royal Society of Chemistry.</Citation></Reference><Reference><Citation>Sun, Y., Chung, D.‐H., Chu, Y.‐K., Jonsson, C. B., &amp; Parker, W. B. (2007). Activity of ribavirin against Hantaan virus correlates with production of ribavirin‐5′‐triphosphate, not with inhibition of IMP dehydrogenase. Antimicrobial Agents and Chemotherapy, 51, 84–88. https://doi.org/10.1128/AAC.00790‐06</Citation></Reference><Reference><Citation>Tararov, V. I., Tijsma, A., Kolyachkina, S. V., Oslovsky, V. E., Neyts, J., Drenichev, M. S., Leyssen, P., &amp; Mikhailov, S. N. (2015). Chemical modification of the plant isoprenoid cytokinin N6‐isopentenyladenosine yields a selective inhibitor of human enterovirus 71 replication. European Journal of Medicinal Chemistry, 90, 406–413. https://doi.org/10.1016/j.ejmech.2014.11.048</Citation></Reference><Reference><Citation>Vasilenko, D. A., Dueva, E. V., Kozlovskaya, L. I., Zefirov, N. A., Grishin, Y. K., Butov, G. M., Palyulin, V. A., Kuznetsova, T. S., Karganova, G. G., Zefirova, O. N., Osolodkin, D. I., &amp; Averina, E. B. (2019). Tick‐borne flavivirus reproduction inhibitors based on isoxazole core linked with adamantane. Bioorganic Chemistry, 87, 629–637. https://doi.org/10.1016/j.bioorg.2019.03.028</Citation></Reference><Reference><Citation>Vitaku, E., Smith, D. T., &amp; Njardarson, J. T. (2014). Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals: Miniperspective. Journal of Medicinal Chemistry, 57, 10257–10274. https://doi.org/10.1021/jm501100b</Citation></Reference><Reference><Citation>Wang, C., Song, Z., Yu, H., Liu, K., &amp; Ma, X. (2015). Adenine: An important drug scaffold for the design of antiviral agents. Acta Pharmaceutica Sinica B, 5, 431–441. https://doi.org/10.1016/j.apsb.2015.07.002</Citation></Reference><Reference><Citation>Wang, Z., Sharma, P. P., Rathi, B., Xie, M., De Clercq, E., Pannecouque, C., Kang, D., Zhan, P., &amp; Liu, X. (2023). Escaping from flatland: Multiparameter optimization leads to the discovery of novel tetrahydropyrido[4,3‐d]pyrimidine derivatives as human immunodeficiency virus‐1 non‐nucleoside reverse transcriptase inhibitors with superior antiviral activities against non‐nucleoside reverse transcriptase inhibitor‐resistant variants and favorable drug‐like profiles. Journal of Medicinal Chemistry, 66(13), 8643–8665. https://doi.org/10.1021/acs.jmedchem.3c00275</Citation></Reference><Reference><Citation>Waye, M. M. Y., &amp; Sing, C. W. (2010). Anti‐viral drugs for human adenoviruses. Pharmaceuticals, 3, 3343–3354. https://doi.org/10.3390/ph3103343</Citation></Reference><Reference><Citation>Ye, N., Chen, H., Wold, E. A., Shi, P.‐Y., &amp; Zhou, J. (2016). Therapeutic potential of spirooxindoles as antiviral agents. ACS Infectious Diseases, 2, 382–392. https://doi.org/10.1021/acsinfecdis.6b00041</Citation></Reference><Reference><Citation>Zha, G.‐F., Rakesh, K. P., Manukumar, H. M., Shantharam, C. S., &amp; Long, S. (2019). Pharmaceutical significance of azepane based motifs for drug discovery: A critical review. European Journal of Medicinal Chemistry, 162, 465–494. https://doi.org/10.1016/j.ejmech.2018.11.031</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>